Departament of Pharmacology and Chemotherapy

The department was established in 1953 by Professor V.A. Shorin. Currently, the lab is headed PhD MD Ivan D. Treschalin

Iv_Tresch    Mirchink_Buchman


  • Head of Lab, PhD MD, Ivan D. Treshalin
  • Leading scientist, ScD, Eleonora R. Pereverzeva
  • Leading scientist, ScD, Elena P. Mirchink
  • Research associate, ScD, Vladimir M. Bukhman
  • Research associate, PhD, Vasilisa A. Golibrodo
  • Research associate, Mikhail I. Treschalin
  • Research associate, Elena B. Isakova
  • Laboratory assistant, Tamara B. Shataeva
  • Laboratory assistant, Marina V. Generalova
  • Laboratory assistant, Olga V. Yampolskaya
  • Laboratory assistant, Oksana S. Belokrysenko
  • Head of vivarium, Michael S. Calesian

Main Research Areas:

  1. The preclinical assessment of the safety of potential new pharmaceuticals;
    1. Acute Toxicity Testing
    2. Subchronic and сhronic toxicity studies, including morphological evaluations of internal organs;
    3. reproductive toxicity, embryo toxicity, and teratogenicity
    4. immunotoxicity
    5. potential for accumulation of effects
    6. local tissue tolerance
    7. mutagenic potential
  2. The preclinical assessment of antitumor activity of new compounds on syngeneic transplantable murine tumors
  3. In vitro and in vivo evaluation of antimicrobial activity of biologically active substances of different origin
  4. The study of drug delivery systems for antitumor and antibacterial antibiotics

Major Achievements:

  • Data on specific (antibacterial, antifungal or antitumor) activity of more than 400 new compounds were obtained. Selected Promising candidates for further research.
  • Preclinical study of the activity and toxicity of more than 40 drugs of different classes was carried out. Documents have been prepared to obtain permission for clinical trials of 5 original target anticancer drugs, 2 antifungal and 1 antibacterial antibiotics developed in GINA.
  • Dicarbamin - new modifier of hematotoxicity of cytostatics - has been studied. The drug is introduced into clinical practice as hematoprotector with intensive anticancer chemotherapy.
  • A preclinical toxicological study of the combined use of ultrasonic hyperthermia and antitumor chemotherapy was carried out. Permission for clinical application of a new method of complex therapy of soft tissue sarcoma was obtained.
  • The principal possibility of reducing cardio - and gonadotoxicity of doxorubicin when used in nanosomal drug formulation has been proved. The drug NanoDox (Drugs Technology Ltd) is in phase 2 clinical trial.
  • The previously unknown property of products of deep lignin hydrolysis to cause ectopic neogenesis of lymph nodes in animal tissues has been experimentally discovered. Received the diploma on the discovery.
  • The property of ascorbigen to increase nonspecific resistance of the organism has been discovered. It was shown, that ascorbigen is a modifier of protective reactions and can be used to reduce toxicity of antitumor drugs.

List of selected references is HERE

Research collaboration:

  • Blokhin Cancer Center, Moscow, Russia
  • National Research Center for Hematology, Moscow, Russia
  • Research institute of human morphology, Moscow, Russia
  • Research Institute of Oncology. N. N. Petrova, Saint-Petersburg, Russia
  • Kurnakov Institute of general and inorganic chemistry RAS
  • Institute of molecular medicine of Sechenov University, Moscow, Russia
  • Center of theoretical problems of physico-chemical pharmacology, Moscow, Russia
  • «Apto-Pharm» LTD, Moscow, Russia
  • «Institute of pharmaceutical technologies» LTD, Moscow, Russia
  • Nanosystem LTD, Moscow, Russia
  • Drugs Technology Ltd, Moscow, Russia

Contacts: Phones: +7(499)245-57-61; E-mail: